This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. (Mladen Antonov/AFP/Getty Images/TNS)

This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. (Mladen Antonov/AFP/Getty Images/TNS)

A look at promising and overhyped COVID therapies after a tumultuous year of research

Here’s a look at some of the drugs – deemed effective and not – that made headlines in recent months

Alongside the headline-grabbing race for a COVID-19 vaccine, the hunt for effective treatments has unfolded with its own share of flameouts and triumphs.

Thanks to large randomized trials in the United Kingdom and elsewhere, administering steroids to patients with moderate or severe illness has become part of standard care, but clinicians say few other tools have emerged.

The best known COVID-19 drug is likely dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant effects for hospitalized patients who need help breathing.

But while that drug is credited with helping efforts to bring down hospital mortality rates, credit also goes to discoveries about what does not work against the novel coronavirus – thereby ensuring people get appropriate care.

Here’s a look at some of the drugs – deemed effective and not – that made headlines in recent months for fostering hype and hope:

Health-Canada approved

Remdesivir – Sold under the name Veklury, this Gilead Sciences drug was among various treatments given to former U.S. President Donald Trump when he successfully overcame COVID-19 last year. But its ability to cut deaths has since been largely discounted by a World Health Organization trial. An earlier study by Gilead found the drug helped moderately ill patients recover more quickly if given for five days, but that benefit was less clear if given over 10 days.

Health Canada noted clinical trial data was limited when it approved remdesivir for COVID-19 last July but said “given the high unmet medical need and emergency context of the COVID-19 pandemic, Health Canada considered the balance of benefit and harm for Veklury to be positive.”

Bamlanivimab – The federal government paid US$32.5 million for 26,000 doses of this monoclonal antibody that targets the spike protein of SARS-CoV-2. Eli Lilly says an intravenous infusion can ease and prevent COVID-19 symptoms among mild-to-moderate cases in high-risk groups including seniors.

Nevertheless, it has yet to be embraced by clinicians, with Hamilton infectious disease physician Zain Chagla calling it “a good example of a drug that might work on paper but really isn’t a great drug to invest in.”

The associate professor of medicine at McMaster University points to barriers to implementation, which include the staffing and time required to implement the transfusion.

Alberta Health Services says it’s considering a trial to determine “potential for benefit and feasibility of use” while British Columbia said Monday a clinical trial in Surrey would be funded by AbCellera, the Vancouver company which helped discover bamlanivimab.

Cautions against early hype

Hydroxychloroquine – Commonly used to treat lupus and rheumatoid arthritis, this drug earned infamy when U.S. President Donald Trump touted its efficacy with COVID-19 before the science was in. Since then, multiple rigorous trials have concluded it offers no benefit to preventing or treating illness while underscoring the dangers of mixing politics and science.

Colchicine –Just last week, the Quebec government cautioned clinicians against embracing this anti-inflammatory as a COVID-19 therapy after the Montreal Heart Institute touted the common gout medication as “a major scientific discovery.” Scientists at the National Institute for Excellence in Health and Social Services acknowledged the institute’s study showed positive results, but said the benefit was too small.

Other contenders

Tocilizumab –Dr. Niall Ferguson, head of critical care at the University Health Network and Sinai Health System, sees potential in early data for tocilizumab, approved for use in Canada to treat rheumatoid arthritis. Although evolving data has been mixed and is still emerging, Ferguson notes the monoclonal antibody is already being used off-label for some severe patients.

Heparin – Canadian scientists involved in a global trial for this blood thinner say interim data suggests it can keep some moderately ill COVID-19 patients from deteriorating further. University Health Network scientist Ewan Goligher says the probability of requiring life support dropped by about a third among subjects. He expects the study’s findings to be released soon.

Peginterferon-lambda – Research into this prospective antiviral treatment was recently published in Lancet Respiratory Medicine. Lead researcher Dr. Jordan Feld, a liver specialist at UHN’s Toronto Centre for Liver Disease, says a small Phase 2 trial found it significantly sped recovery for outpatients. Although more research is needed, he suspected it could offer an important way to quickly bring down the virus level in infected patients and reduce their risk of spreading disease to others.

Cassandra Szklarski, The Canadian Press

Like us on Facebook and follow us on Twitter.

Want to support local journalism? Make a donation here.

Coronavirus

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Ocean Scheerschmidt, and her dad Brad, raised $1,100 for an Alberta-based veteran support program. 
Kevin J. Sabo photo
A Castor youth has fundraised for an organization dedicated to helping military veterans and first responders

The Hoggin Alberta Veterans Ranch is receiving an $1,100 donation from ten-year-old Ocean Scheerschmidt

A health care worker prepares to test a Coastal GasLink field worker for COVID-19. (Coastal GasLink photo)
Alberta bill would protect health workers, care homes from some COVID-19 lawsuits

The bill proposes exempting a range of workers, including doctors, pharmacists and care-home operators from being sued over COVID-19 – unless for gross negligence

pic
Main Street construction to commence on May 1st

The project will include new concrete sidewalks, enhanced bulbing features, and watermain replacements

Nineteen-year-old Amanda enjoys a ride during a visit to Spirit’s Respite Ranch near Stettler. photo submitted
Busy days at Spirit’s Respite Ranch near Stettler

The ranch, which launched operations last summer, provides support through animal interaction

Alberta chief medical officer of health Dr. Deena Hinshaw said on Thursday that the province has seen its first case of the B.1.617 variant. (Photography by Chris Schwarz/Government of Alberta)
Red Deer nears record number of active COVID-19 cases

Alberta reports 1,857 new cases of COVID-19, 1,326 new variants

A nurse gets a swab ready to perform a test on a patient at a drive-in COVID-19 clinic in Montreal, on Wednesday, October 21, 2020. THE CANADIAN PRESS/Paul Chiasson
Alberta reports first case of another new variant as daily COVID-19 cases rise

Hinshaw says it was brought to Alberta by an interprovincial traveller

A health-care worker prepares a dose of the Pfizer-BioNTech COVID-19 vaccine at a clinic in Toronto on Thursday, January 7, 2021. THE CANADIAN PRESS/Nathan Denette
Canada buys 65M Pfizer booster shots for protection against COVID-19 variants

Prime Minister Justin Trudeau says the deal with Pfizer includes options to add 30 million doses in both 2022 and 2023, and an option for 60 million doses in 2024

Steam billows from the Sheerness coal-fired generating station near Hanna, Alta., Tuesday, Dec. 13, 2016.THE CANADIAN PRESS/Jeff McIntosh
Alberta didn’t consider impact of mountain coal mining on tourism: official

Justin Brattinga, spokesman for current minister Doug Schweitzer, said the tourism strategy is being completely revised

Alberta auditor general Doug Wylie speaks at a news conference in Edmonton on Friday, Oct. 4, 2019. THE CANADIAN PRESS/Jason Franson
Alberta auditor general finds CT and MRI tests confused, antiquated

In 2018-19, Alberta performed 647,000 combined MRI and CT exams at a cost of more than $170 million

pic
Main Street construction to commence on May 1st

The project will include new concrete sidewalks, enhanced bulbing features, and watermain replacements

Journal de Montreal is seen in Montreal, on Thursday, April 22, 2021. The daily newspaper uses a file picture of Prime Minister Justin Trudeau dressed in traditional Indian clothing during his trip to India to illustrate a story on the Indian variant of the coronavirus. Paul Chiasson/The Canadian Press
Montreal newspaper blasted for front-page photo of Trudeau in India

Trudeau is wearing traditional Indian clothes and holding his hands together in prayer beside a caption that reads, ‘The Indian variant has arrived’

Education Minister Adriana LaGrange was in Red Deer on Friday to provide an update on the province's COVID-19 response in schools.
Photo by PAUL COWLEY/Advocate staff
Alberta government aiming to boost financial literacy among students

Government providing grants to organizations who will help design financial literacy programming

President Joe Biden holds a virtual bilateral meeting with Canadian Prime Minister Justin Trudeau. (AP Photo/Evan Vucci)
U.S. to help Canada with more COVID-19 vaccine supply, Biden says

The U.S. has already provided Canada with about 1.5 million doses of the AstraZeneca vaccine

Most Read